DCSIMG
AMBIEN® CR (zolpidem tartrate) Tools & Resources

Related Links

These resources can offer additional information on sleep-related issues.

Organizations
National Sleep Foundation

Sleep disorders information; publications; advocacy initiatives (legislation); annual Sleep in America Poll.
http://www.sleepfoundation.org/

Sign up for the National Sleep Foundation e-newsletter.
http://www.sleepfoundation.org/site/apps/ka/ct/contactus.asp?c=huIXKjM0IxF&b=2488325

National Institutes of Health (NIH)

Main sleep disorders page for the NIH. Includes links to information from the various Institutes and Centers of the NIH.
http://health.nih.gov/result.asp/601/3

American Academy of Sleep Medicine

Directory of accredited sleep centers; information for public and professionals.
http://www.aasmnet.org/

National Center on Sleep Disorders Research (National Institutes of Health)

Information and publications; sleep quiz; Sleep in Youth/Drowsy Driving information.
http://www.nhlbi.nih.gov/about/ncsdr/index.htm

Books

There are a number of informative books written about sleep and insomnia. Contact a sleep association or talk to your local librarian or bookseller for some specific suggestions.

pagedivide

* Maximum benefit is $240 off, up to $20 off each prescription (up to 12 prescriptions), depending on your out-of-pocket costs. Not valid for patients participating in Medicare, Medicaid, government (public insurance) programs, or any private payor in the state of Massachusetts and where prohibited by law.

AMBIEN CR is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

IMPORTANT SAFETY INFORMATION

In elderly or debilitated patients, or patients with hepatic insufficiency, the recommended dose is 6.25 mg and patients should be closely monitored. Due to its rapid onset of action, patients should take AMBIEN CR right before going to bed and when ready for sleep. Patients should not take AMBIEN CR unless they are prepared to get a full night’s sleep (7 to 8 hours) to avoid residual effects. Until they know how it will affect their physical or mental performance upon awakening, patients should not drive or operate hazardous machinery after taking AMBIEN CR or any other sleep medication. Complex behaviors such as somnambulism, including driving or eating while not fully awake, with amnesia for the event, as well as abnormal behaviors such as being more outgoing or aggressive than normal, confusion, agitation, and hallucinations may occur. AMBIEN CR should not be taken with alcohol as it may increase these abnormal behaviors. Discontinuation of AMBIEN CR should be strongly considered for patients reporting such complex behaviors. Angioedema may occur in patients taking AMBIEN CR and in rare cases may be fatal. Patients who develop angioedema should not be rechallenged. In primarily depressed patients, worsening of depression, including risk of suicidal thoughts or actions, including completed suicides, have been reported. The most commonly observed adverse effects in controlled clinical trials were headache, somnolence, and dizziness. Because individuals with a history of addiction or substance abuse are at increased risk of habituation and dependence, they should be under careful surveillance when receiving AMBIEN CR or any other hypnotic. AMBIEN CR is a Schedule IV controlled substance.

Please refer to the full prescribing information.